정상 신장 기능 참여자와 비교한 심각한 신장애 성인에서 정제 rilzabrutinib의 혈장 농도 평가

The purpose of this Phase 1, open-label, 2-arm study is to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75 years. The total duration of the study per participant will be approximately 30 days, including: * A screening period of up to 27 days. * A 3-day, open-label treatment period, with a single dose on Day 1. * A 1-day follow-up period (Day 3) with an allowable 2-day window (ie, Day 3 to Day 5).